Funding News

Confido Health Raises $12.5M Series A Extension Led by Z47 to Scale AI-Driven Healthcare Administration

By Mustafa Shariff, Editor in Chief · October 19,2026 · 2 mins read

Mustafa Shariff, Editor in Chief — Confido Health Raises $12.5M Series A Extension Led by Z47 to Scale AI-Driven Healthcare Administration

Summary

  • Confido Health raises $12.5M Series A extension led by Z47 to scale AI healthcare administration
  • Confido Health, the AI-powered healthcare administration startup co-founded by Chetan Reddy and Vichar Shroff, has raised $12.5M in a Series A extension led by Z47, with participation from Together Fund, Blume Ventures, and strategic investor Justin Saks. The round brings total Series A funding to $22.5M.

"AI handling rates above 95% across a million patient tasks — Confido is automating the work no one wanted to do, at a scale that is hard to ignore."

Confido Health builds AI agents that automate the administrative layer of healthcare delivery — the calls, forms, verifications, and follow-ups that consume enormous staff time without directly improving clinical outcomes. Its flagship platform, CareOS, integrates with more than 50 healthcare systems, including electronic health records (EHRs), practice management software, and revenue cycle management (RCM) tools, allowing healthcare providers to deploy AI agents without replacing any existing technology. Key workflows handled include inbound and outbound patient calls, appointment scheduling and reminders, insurance eligibility verification, prescription refill processing, and patient payment collection. A distinguishing feature is that CareOS links related tasks — a single patient call can trigger automatic appointment booking, insurance check, and payment follow-up — reducing the need for staff to hand tasks off between systems.
The $12.5M Series A Extension — Round Details
The $12.5M raise is structured as an extension of Confido Health's Series A, bringing the total for that round to $22.5M. Z47 — formerly known as Matrix Partners India, one of India's most established early-stage venture capital firms, with a portfolio spanning Ola, Razorpay, and Practo — led the extension. Existing investors Together Fund and Blume Ventures (both Bengaluru-based and active in cross-border healthtech) participated. The round also welcomed Justin Saks, a healthcare private equity specialist, as both investor and board adviser. His involvement reflects Confido's primary growth motion: reaching multi-site healthcare groups through the PE firms that own them, rather than going hospital-by-hospital through traditional sales cycles.
Traction: 3,200+ Providers, 15× Growth
Confido Health reports 3,200+ providers across more than 1,500 sites in 27 US states. The company claims 15-fold growth since its previous funding round — the metric for that multiple was not specified publicly. On performance: AI agents are completing more than one million tasks with a reported handling rate above 95% for key workflows and an average patient satisfaction score of 4.55 out of 5. These figures are company-reported and not independently verified, but the combination of volume, handling rate, and satisfaction metrics across a large provider base constitutes one of the more detailed sets of operational data released by an early-stage healthcare AI company. The breadth of state coverage (27 of 50 US states) also suggests the platform has cleared the EHR and payer integration hurdles that trip up many healthcare AI entrants.
Founders: Chetan Reddy and Vichar Shroff
Confido Health was co-founded in 2022 by Chetan Reddy and Vichar Shroff. The company is headquartered in the US and targets the American healthcare market, but has strong Indian VC backing — Z47, Blume Ventures, and Together Fund are all India-headquartered or India-focused funds. This reflects a pattern increasingly common in global healthtech: product built for the US market, founding team with Indian roots, early institutional backing from Indian VCs who invest cross-border. Confido started with voice AI for patient phone calls and progressively expanded into the broader administrative stack as it demonstrated that AI could reliably handle the phone channel.
Use of Funds: Deeper Penetration of PE-Backed Health Groups
The fresh capital will be deployed across two priorities. First, expanding CareOS penetration across healthcare organisations with multiple sites — particularly those owned by private equity firms, which represent a concentrated and rapidly growing segment of US healthcare. Multi-site PE-backed medical groups are operationally motivated to standardise and automate administration across their portfolio companies, making them a natural fit for a platform like CareOS. Second, developing AI agents for additional workflows and medical specialities beyond the current core — extending coverage from general practice administration into specialty care administration such as orthopaedics, dermatology, and surgical scheduling.
Why Z47's Bet Makes Sense — and What It Signals
Z47 has backed some of India's most successful consumer-internet and fintech companies, but has been steadily increasing its bets on global SaaS and AI. Confido Health sits at an intersection Z47 understands well: B2B software that automates processes for fragmented, underserved markets. US healthcare administration is a $400+ billion annual cost line for the industry — roughly a third of total US healthcare spending. The market is enormous, the pain is severe, and the AI penetration rate remains low despite years of hype. For Z47, Confido represents a disciplined AI SaaS bet with real operational metrics rather than a speculative platform play. The entry of Justin Saks as PE-network adviser also suggests a deliberate channel strategy: Z47's network helps in India; Saks' PE relationships accelerate US enterprise sales.
BHC Perspective: India-Born AI Solving America's Healthcare Admin Crisis
India's healthcare system battles a different set of administrative burdens — but the underlying challenge of administrative overhead consuming clinical bandwidth is universal. Confido Health's success in the US is relevant to the Indian market not because CareOS will immediately land here, but because it validates a broader thesis: AI agents can reliably handle high-volume, rule-bound healthcare workflows at a quality that satisfies both patients and providers. Indian healthtech companies building for domestic healthcare administration — Ayushman Bharat's digital health stack, the insurance pre-authorisation backlog at PMJAY, hospital discharge documentation delays — should study Confido's product architecture and operating metrics closely. The company demonstrates that the technical problem is largely solved; what remains is the integration, trust, and regulatory work that differs by market.
Frequently Asked Questions
Q: What is CareOS and how does it differ from regular healthcare chatbots?
A: CareOS is Confido Health's AI platform that integrates directly with existing healthcare systems — EHRs, practice management software, and billing tools — rather than operating as a standalone chatbot. Unlike a generic chatbot that answers pre-scripted questions, CareOS AI agents can take actions: they can book appointments, verify insurance eligibility, process refill requests, and collect payments, all within the same patient interaction. The system also chains related tasks, so a single patient call can automatically trigger booking, verification, and payment follow-up without staff involvement. The 95%+ handling rate suggests the agents are completing full workflows, not just answering queries.
Q: What is Z47 (formerly Matrix Partners India) and why does its involvement matter?
A: Z47 rebranded from Matrix Partners India in 2023 after separating from its US affiliate Matrix Partners. The fund has been one of India's most active and successful early-stage VCs, with a portfolio that includes Ola, Razorpay, Practo, and Dailyhunt. It manages over $1 billion in assets. Its investment in Confido Health — a US-market company — reflects Z47's growing ambition to back cross-border companies founded by Indian entrepreneurs or with India-based institutional backing. Z47's network in India's healthcare and SaaS ecosystem may also provide Confido with potential future international expansion pathways.
Q: Does Confido Health operate in India?
A: As of this funding round, Confido Health's platform and customer base are focused exclusively on the US market. Its 3,200+ providers and 1,500+ sites are all US-based. The company has strong India ties through its investors (Z47, Blume Ventures, Together Fund) and its founding team's background, but has not announced India-specific product or market plans. Use of funds from this round is directed at deepening US market penetration, particularly within PE-backed multi-site health groups.
Q: Why is the US healthcare administration market so large — and so ripe for AI?
A: The US spends an estimated $400–500 billion annually on healthcare administration — roughly 30–35% of total healthcare expenditure — compared to 12–15% in other high-income countries. This overhead is driven by the complexity of a multi-payer insurance system, high regulatory compliance burden, fragmented provider technology landscape, and historical reliance on manual, phone-based workflows. AI agents are well-suited to this environment because the tasks are high-volume, rule-bound, and repetitive — exactly the type of work that machine learning and LLM-based voice agents can automate reliably. Confido's 95% AI handling rate across a million tasks suggests these workflows are now automatable at production quality.